Inhibitors of c-Jun N-terminal kinases—JuNK no more?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The c-Jun N-terminal kinases (JNKs) have been the subject of intense interest since their discovery in the early 1990s. Major research programs have been directed to the screening and/or design of JNK-selective inhibitors and testing their potential as drugs. We begin this review by considering the first commercially-available JNK ATP-competitive inhibitor, SP600125. We focus on recent studies that have evaluated the actions of SP600125 in lung, brain, kidney and liver following exposure to a range of stress insults including ischemia/reperfusion. In many but not all cases, SP600125 administration has proved beneficial. JNK activation can also follow infection, and we next consider recent examples that demonstrate the benefits of SP600125 administration in viral infection. Additional ATP-competitive JNK inhibitors have now been described following high throughput screening of small molecule libraries, but information on their use in biological systems remains limited and thus these inhibitors will require further evaluation. Peptide substrate-competitive ATP-non-competitive inhibitors of JNK have also now been described, and we discuss the recent advances in the use of JNK inhibitory peptides in the treatment of neuronal death, diabetes and viral infection. We conclude by raising a number of questions that should be considered in the quest for JNK-specific inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“The benefits of lowering JNK-dependent signalling in diabetes were first seen in JNK gene knockout studies [96, 97] .”
BackgroundDérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188 · cited 2×
“In late 2001, the small molecule JNK inhibitor, SP600125 (anthra[1,9]pyrazol-6(2H)-one), was reported following the screening of a proprietary library (Celgene/Signal Pharmaceuticals) for inhibitors of JNK2 activity towards the c-Jun transactivation domain [4].”
BackgroundSP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 2×
“Notably, serum and glucocorticoidregulated kinase, p70 ribosomal S6 kinase, AMP-dependent protein kinase, cyclin dependent kinase 3, casein kinase 1δ and dual-specificity tyrosine–regulated kinase 1Awere all inhibited by 10 μM SP600125 to a greater extent than the inhibition observed for JNK [50].”
BackgroundA Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway
Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J. R., Greenberg, M. E., Sawyers, C. L., & Davis, R. J. (1997) · Science · doi:10.1126/science.277.5326.693 · Cited by 675 · cited 1×
“Of note, JIP1 was first described to inhibit JNK by preventing JNK nuclear translocation, but a short conserved sequence was also identified as critical for the JIP1–JNK interaction [74].”
BackgroundA peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658 · cited 1×
“This highlighted the success of these peptides in blocking pancreatic β-cell death [76], cerebral ischemia/stroke [77,84], and hearing loss induced by aminoglycosides and acoustic trauma [85].”
BackgroundCell-Permeable Peptide Inhibitors of JNK
Bonny, C., Oberson, A., Negri, S., Sauser, C., & Schorderet, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.1.77 · Cited by 571
C-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity
Gunawan, B. K., Liu, Z., Han, D., Hanawa, N., Gaarde, W. A., & Kaplowitz, N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.045 · Cited by 471 · cited 1×
“Marked protective effects of SP600125 was observed for acetaminophen-induced toxicity both in vitro and in vivo, through the actions of SP600125 were observed to block apoptotic cell death [19].”
BackgroundFunctional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance
Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M., & Hotamisligil, G. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603509103 · Cited by 350 · cited 1×
“Why earlier studies using JNK inhibitors, the overexpression of dominant-negative JNK mutants, or gene knockout studies (e.g. [98, 107, 108] ) have not observed similar changes remains to be established.”
Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
Heo, Y., Kim, S., Seo, C. I., Kim, Y. K., Sung, B., Lee, H. S., Lee, J. I., Park, S., Kim, J. H., Hwang, K. Y., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600212 · Cited by 275 · cited 1×
“These JIP-derived peptides inhibitors have been shown kinetically to act in a protein substrate-competitive manner [79], and by cocrystallisation and mutagenesis studies to bind directly to the putative protein substrate docking domain of JNK [80,81].”
BackgroundIdentification of the Critical Features of a Small Peptide Inhibitor of JNK Activity
Barr, R. K., Kendrick, T. S., & Bogoyevitch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107565200 · Cited by 211 · cited 1×
“Short JIP-derived peptides have been subsequently shown to inhibit JNK activity in vitro [75] .”
BackgroundSelf-citationThe Structure of JNK3 in Complex with Small Molecule Inhibitors
Scapin, G., Patel, S. B., Lisnock, J., Becker, J. W., & LoGrasso, P. V. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00159-5 · Cited by 131 · cited 7×
“SP600125 High throughput screening of Celgene compound collection using JNK2 activity assay, followed by cell-based testing IC50 JNK1=40 nM IC50 JNK2 =40 nM IC50 JNK3=90 nM 1UKI 1PMV [5]”
BackgroundMethodInfluential
Cited by
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Keshet, Y., & Seger, R. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-795-2_1 · Cited by 642
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships
Zeke, A., Misheva, M., Reményi, A., & Bogoyevitch, M. A. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00043-14 · Cited by 523
Self-citationTanti, J.-F., & Jager, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.07.004 · Cited by 430
c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease
Yarza, R., Vela, S., Solas, M., & Ramirez, M. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00321 · Cited by 410
Metadata
- Authors
- Bogoyevitch, M. A., & Arthur, P. G.
- Venue
- Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 1784
- Issue
- 1
- Pages
- 76-93
- ISSN
- 1570-9639 (ISSN-L)
- OpenAlex
- W2094948453
- Cited by
- 127
- References
- 13
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.